Details of Disease

General Information of Disease (ID: DISD18PM)

• Disease Name: Chronic heart failure
• Disease Class: BD10-BD1Z: Heart failure
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISD18PM: Chronic heart failure
• ICD Code:
  ICD-11: ICD-11: BD1Z
  ICD-10: ICD-10: I50, I50.9
  ICD-9: ICD-9: 428
  Expand ICD-9: 428
• Disease Identifiers:
  MedGen ID: 538783
  SNOMED CT ID: 48447003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 20 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amlodipine	DMBDAZV	Approved	Small molecular drug	[1]
Candesartan	DMRK8OT	Approved	Small molecular drug	[2]
Captopril	DM458UM	Approved	Small molecular drug	[3]
Carvedilol	DMHTEAO	Approved	Small molecular drug	[4]
Celacade	DM87CRX	Approved	NA	[5]
Chlorothiazide	DMLHESP	Approved	Small molecular drug	[6]
Digoxin	DMQCTIH	Approved	Small molecular drug	[7]
Dipyridamole	DMXY30O	Approved	Small molecular drug	[8]
Fosinopril	DM9NJ52	Approved	Small molecular drug	[9]
Hydralazine	DMU8JGH	Approved	Small molecular drug	[10]
Hydrochlorothiazide	DMUSZHD	Approved	Small molecular drug	[11]
Isosorbide Dinitrate	DMBI4JG	Approved	Small molecular drug	[12]
Ivabradine	DM0L594	Approved	Small molecular drug	[13]
Lisinopril	DMUOK4C	Approved	Small molecular drug	[14]
Metoprolol	DMOJ0V6	Approved	Small molecular drug	[15]
Quinapril	DMR8H31	Approved	Small molecular drug	[16]
Ramipril	DM2R68E	Approved	Small molecular drug	[17]
Spironolactone	DM2AQ5N	Approved	Small molecular drug	[18]
Trandolapril	DM4L6EU	Approved	Small molecular drug	[19]
Valsartan	DMREUQ6	Approved	Small molecular drug	[20]

This Disease is Treated as An Indication in 13 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Neucardin	DME617W	Phase 3	NA	[21]
Recombinant human neuregulin-1 beta	DM9DBAU	Phase 3	NA	[22]
C-Cure	DMLDN6J	Phase 2/3	NA	[23]
Subcutaneous furosemide	DMS49L2	Phase 2/3	NA	[21]
CLP-1001	DMH2VS0	Phase 2	NA	[24]
CLR325	DMP83PP	Phase 2	NA	[21]
Mesenchymal stem cell therapy	DMW7QYT	Phase 2	NA	[21]
Neladenoson bialanate	DMSVWI7	Phase 2	NA	[21]
ANX-042	DM7XES6	Phase 1	NA	[25]
BMS-986224	DMUXEPH	Phase 1	NA	[21]
JTT-861	DM9M1K0	Phase 1	NA	[26]
LY3461767	DMYRA5I	Phase 1	NA	[27]
mRNA-0184	DM4LS5W	Phase 1	mRNA	[28]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Amlodipine FDA Label
• [2] Candesartan FDA Label
• [3] Captopril FDA Label
• [4] Carvedilol FDA Label
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Chlorothiazide FDA Label
• [7] Digoxin FDA Label
• [8] Dipyridamole FDA Label
• [9] Fosinopril FDA Label
• [10] Hydralazine FDA Label
• [11] Hydrochlorothiazide FDA Label
• [12] Isosorbide dinitrate FDA Label
• [13] Ivabradine FDA Label
• [14] Lisinopril FDA Label
• [15] Metoprolol FDA Label
• [16] Quinapril FDA Label
• [17] Ramipril FDA Label
• [18] Spironolactone FDA Label
• [19] Trandolapril FDA Label
• [20] Valsartan FDA Label
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [22] ClinicalTrials.gov (NCT01214096) Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure. U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT00810238) C-Cure Clinical Trial. U.S. National Institutes of Health.
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034446)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036485)
• [26] Clinical pipeline report, company report or official report of Akros Pharma
• [27] ClinicalTrials.gov (NCT04840914) A Single-Dose Study Evaluating Different Dose Levels and Subcutaneous Infusion Durations on Safety, Pharmacokinetics, and Pharmacodynamics of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction. U.S.National Institutes of Health.
• [28] ClinicalTrials.gov (NCT05659264) A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants With Chronic Heart Failure. U.S.National Institutes of Health.